Nivolumab The risk or severity of adverse effects can be increased when Tocilizumab is combined with Nivolumab. Nomegestrol The metabolism of Nomegestrol can be increased when combined with Tocilizumab. Nomegestrol acetate The metabolism of Nomegestrol acetate can be increased when combined with Tocilizumab...
Nivolumab The risk or severity of adverse effects can be increased when Nivolumab is combined with Blinatumomab. Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Blinatumomab. Obiltoxaximab The risk or severity of adverse effects can be increased when ...
After the description of their mechanism of action, the clinical applications of anti-CTLA-4 mAbs ipilimumab and tremelimumab, anti-PD1-antibodies nivolumab and pembrolizumab, and the anti-PD-L1-antibodies are presented. The ICIs are used mainly in inoperable and advanced tumors, but this fact is...
et al. Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma. Ann. Oncol. 27 (suppl.), abstract 22LBA, in the press (2015). El-Khoueiry, A. B. et al. Phase I/II safety and antitumor activity of nivolumab in patients ...
Dr Werutsky on the Effects of HER2-Low Breast Cancer Subtype on Treatment Outcomes Dr Kalinka on Frontline BMS-986012 Plus Nivolumab and Chemotherapy in ES-SCLC Dr Garje on Unmet Needs in Small Cell Bladder Cancer Dr Parikh on the Clinical Implications of Molecular Testing on mCRC Management ...
Samer A. Srour, MB ChB, MS, discusses the mechanism of action of ALLO-316, which is being investigated for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma, and details safety findings from the phase 1 TRAVERSE study
The interaction of PD1 expressed in T cells with PD-L1 on cancer cells suppresses the proliferation and survival of T cells, which ultimately leads to immunosuppression. Pembrolizumab and nivolumab are ICIs that target PD1 to prevent PD1/PD-L1 interaction [19]. In contrast, atezolizumab and durva...
The interaction of PD1 expressed in T cells with PD-L1 on cancer cells suppresses the proliferation and survival of T cells, which ultimately leads to immunosuppression. Pembrolizumab and nivolumab are ICIs that target PD1 to prevent PD1/PD-L1 interaction [19]. In contrast, atezolizumab and durva...
resistant cancer. This series of novel therapeutic regimens has spurred the development of triplet regimens. In an ongoing phase I trial (NCT04840589), ZEN003694 and nivolumab alone or combined with ipilimumab were assessed in PROC patients. In addition, another combination therapy comprising CDX-...
Nivolumab The risk or severity of adverse effects can be increased when Nivolumab is combined with Anifrolumab. Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Anifrolumab. Obiltoxaximab The risk or severity of adverse effects can be increased whe...